Compare Sanofi SA (SNY) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs AT&T Inc. — how do they compare? Sanofi SA trades at $43.59 (market cap $104.30B), while AT&T Inc. trades at $24.1 (market cap $167.88B). The key difference: AT&T Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | T | |
|---|---|---|
Market Cap | $104.30B | $167.88B |
Sector | Health | Media |
52-Week High | $52.34 | $29.62 |
52-Week Low | $41.33 | $20.49 |
Enterprise Value | $124.19B | $313.20B |
Dividend Yield | 5.55% | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
AT&T (T) trades at $24.19, up 0.46% today, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights its focus on fiber expansion and AI integration, while cash flow improved to $15.12B net in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14.5% upside, supported by a 4.8% dividend yield. Risks include competitive pressure from SpaceX's Starlink and high debt levels. Analysts are mixed but lean bullish, with 41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
